Listed

GridAI Technologies Corp.: Form 10-Q for the period ended Jun 30, 2023

Filed with the SEC on Aug 14, 2023 and accepted by EDGAR at Aug 14, 2023, 16:16 ET.

Share

Management's discussion and analysis

As filed, 20,073 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

References in this report to “First Wave,” “AzurRx,” “Company,” “we,” “us,” “our,” or similar references mean First Wave BioPharma, Inc. and its subsidiaries on a consolidated basis. References to “First Wave BioPharma” refer to First Wave BioPharma, Inc. on an unconsolidated basis. References to “AzurRx SAS” refer to First Wave BioPharma’s former wholly owned subsidiary through which we previously conducted our European operations. References to the “SEC” refer to the U.S. Securities and Exchange Commission.

Forward-Looking Statements

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our consolidated financial statements and the related notes included elsewhere in this interim report. Our consolidated financial statements have been prepared in accordance with U.S. GAAP. The following discussion and analysis contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including, without limitation, statements regarding our expectations, beliefs, intentions or future strategies that are signified by the words “expect,” “anticipate,” “intend,” “believe,” or similar language. All forward-looking statements included in this document are based on information available to us on the date hereof, and we assume no obligation to update any such forward-looking statements. Our business and financial performance are subject to substantial risks and uncertainties. Actual results could differ materially from those projected in the forward-looking statements. In evaluating our business, you should carefully consider the information set forth under the heading “Risk Factors” included in our Annual Report filed on Form 10-K for the year ended December 31, 2022 filed with the SEC on March 20, 2023. Readers are cautioned not to place undue reliance on these forward-looking statements.

Overview

We are engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (“GI”) diseases. Non-systemic therapies are non-absorbable drugs that act locally, i.e., in the intestinal lumen, skin or mucosa, without reaching an individual’s systemic circulation.

We are currently focused on developing our pipeline of gut-restricted GI clinical drug candidates, including the biologic adrulipase (formerly MS1819), a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, and niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties.

Our adrulipase programs are focused on the development of an oral, non-systemic, biologic capsule for the treatment of exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis (“CF”) and chronic pancreatitis (“CP”). Our goal is to provide CF and CP patients with a safe and effective therapy to control EPI that is non-animal derived and offers the potential to dramatically reduce their daily pill burden. In March 2021, we announced topline results from our Phase 2b OPTION 2 monotherapy trial, and in 2021, we announced positive topline results from our Phase 2 Combination trial in Europe. In November 2022 we filed a Phase 2b investigational new drug (“IND”) amendment for a bridging study using a new enteric microgranule formulation of adrulipase with the U.S. Food and Drug Administration (“FDA”). We initiated the Phase 2b monotherapy trial during the first quarter of 2023 and announced initial topline data in July 2023. While the initial data from the study indicated that the enhanced adrulipase formulation was safe and well tolerated and demonstrated an improvement over prior formulations of adrulipase, it also indicated that it is likely that the primary efficacy endpoint was not achieved. We are continuing to assess the data and expect to report additional findings on primary and secondary endpoints in the third quarter of 2023.

Our niclosamide programs leverage proprietary oral and topical formulations to address multiple GI conditions, including inflammatory bowel diseases (“IBD”) indications. In 2022 we advanced two separate Phase 2 clinical programs of our niclosamide formulations, including FW-COV for Severe Acute Respiratory Syndrome Coronavirus 2 (“COVID-19”) GI infections, and FW-UP for ulcerative proctitis (“UP”) and ulcerative proctosigmoiditis (“UPS”).

We announced the completion of enrollment in the FW-COV trial in January 2022 and topline results in August 2022. In September 2022 we announced that we would no longer pursue the anti-viral COVID-GI clinical indication as a result of the mixed results from the FW-COVID-19 trial. Additionally, we are devoting fewer resources to the FW-UP/UPS niclosamide program due to inconclusive data from a small Phase 2 trial in Europe, the need for a new FDA-IND cleared protocol, and financial constraints.

We are further developing FW-ICI-AC for Immune Checkpoint Inhibitor-associated colitis (“ICI-AC”) and diarrhea in advanced stage oncology patients, which received FDA IND clearance for a Phase 2a clinical trial in October 2021, and two pre-IND programs of our niclosamide therapies for additional IBD indications, including FW-UC for ulcerative colitis (“UC”) and FW-CD for Crohn’s disease (“CD”). However, the FW-ICI-AC program is currently on hold due to financial constraints.

Liquidity and Capital Resources

To date, we have not generated any revenues and have experienced net losses and negative cash flows from our activities.

As of June 30, 2023, we had cash and cash equivalents of approximately $1.2 million, and had sustained cumulative losses attributable to common stockholders of approximately $176.8 million. Subsequent to June 30, 2023 through August 14, 2023, we have raised aggregate gross proceeds of approximately $2.1 million from the July 2023 Offering. We anticipate having sufficient cash to fund planned operations through September 2023, however, the acceleration or reduction of cash outflows by management can significantly impact the timing for the need to raise additional capital to complete development of our products. We have not yet achieved profitability and anticipate that we will continue to incur net losses for the foreseeable future. We expect that our expenses will continue to grow and, as a result, we will need to generate significant product revenues to achieve profitability. We may never achieve profitability. As such, we are dependent on obtaining, and are continuing to pursue, the necessary funding from outside sources, including obtaining additional funding from the sale of securities in order to continue our operations. Without adequate funding, we may not be able to meet our obligations. We believe these conditions may raise substantial doubt about our ability to continue as a going concern.

We have funded our operations to date primarily through the issuance of debt, convertible debt securities, preferred stock, as well as the issuance of Common Stock in various public offerings and private placement transactions. We expect to incur substantial expenditures in the foreseeable future for the development of adrulipase, niclosamide and any other drug candidates. We will require additional financing to develop our drug candidates, run clinical trials, prepare regulatory filings and obtain regulatory approvals, fund operating losses, and, if deemed appropriate, establish manufacturing, sales and marketing capabilities. Our current financial condition raises substantial doubt about our ability to continue as a going concern. Our failure to raise capital as and when needed would have a material adverse impact on our financial condition, our ability to meet our obligations, and our ability to pursue our business strategies. We will seek funds through additional equity and/or debt financings, collaborative or other arrangements with corporate sources, or through other sources of financing.

Although, we are primarily focused on the development of our drug candidates, including adrulipase and niclosamide, we are also opportunely focused on expanding our product pipeline of clinical assets through collaborations, and also through acquisitions of products and companies. We are continually evaluating potential asset acquisitions business combinations, and other partnership opportunities. To finance such acquisitions, we might raise additional equity capital, incur additional debt, or both.

We are able to sell securities on a shelf registration statement pursuant to the ATM Agreement with H.C. Wainwright & Co., LLC. Under current SEC regulations, because our public float was less than $75 million at the relevant measurement period pursuant to General Instruction I.B.6. to Form S-3, the amount we can raise through primary public offerings of securities in any subsequent twelve-month period under our shelf registration statement is limited to an aggregate of one-third of our public float until such time, if any, as our public float is $75 million or more. As a result, we are currently restricted from using the ATM Agreement.

Our ability to issue securities is subject to market conditions. Each issuance under the shelf registration statements will require the filing of a prospectus supplement identifying the amount and terms of the securities to be issued.

Consolidated Results of Operations for the Three Months Ended June 30, 2023 and 2022

The following table summarizes our consolidated results of operations for the periods indicated:

​ ​ ​ ​ Operating expenses: ​ ​ ​ ​ Three Months Ended June 30, 2023 ​ ​ ​ ​ 2022 ​ ​ ​ ​ ​ ​ ​ ​ Increase (decrease) ​
Research and development expenses ​ $1,353,095 ​ $2,906,896 ​ $(1,553,801)
General and administrative expenses ​ ​ 2,828,549 ​ ​ 2,498,957 ​ ​ 329,592
Total operating expenses ​ 4,181,644 ​ 5,405,853 ​ (1,224,209)
Other expenses ​ 7,588 ​ 2,292 ​ 5,296
Net loss ​ $4,189,232 ​ $5,408,145 ​ $(1,218,913)

Research and Development Expenses

Research and development expenses include expenses primarily relating to the development of our adrulipase and niclosamide drug candidates.

Research and development expenses for the three months ended June 30, 2023 totaled approximately $1.4 million, a decrease of approximately $1.5 million, or 53%, over the approximately $2.9 million recorded for the three months ended June 30, 2022.

The decrease in research and development expenses was primarily attributable to decreases of approximately $0.6 million in clinical related expenses in connection with our Phase 2b adrulipase SPAN clinical trial during the three months ended June 30, 2023, as compared to our Phase 2 RESERVOIR COVID-19 GI clinical trial during the three months ended June 30, 2022, approximately $0.6 million in manufacturing costs related to adrulipase, as well as approximately $0.3 million in personnel related costs.

We expect research and development expenses to decrease during the remainder of this fiscal year as we close out the Phase 2b adrulipase SPAN clinical trial.

General and Administrative Expenses

General and administrative expenses include expenses primarily relating to our overall operations and being a public company, including personnel, legal and financial professional services, insurance, corporate communication and investor relations, listing and compliance related costs, rent, and expenses associated with obtaining and maintaining intellectual property and patents, among others.

General and administrative expenses for the three months ended June 30, 2023 totaled approximately $2.8 million, an increase of approximately $0.3 million, or 13% over the approximately $2.5 million recorded for the three months ended June 30, 2022.

The increase in general and administrative expenses was primarily due to increases of approximately $0.6 million in public company costs, including investor relations and corporate communications, partially offset by decreases of approximately $0.3 million in professional fees and other corporate costs.

We expect general and administrative expenses to remain stable during the remainder of this fiscal year.

Other Expenses

Other expenses for the three months ended June 30, 2023 totaled approximately $7,600, an increase of approximately $5,300, or 231% over the approximately $2,300 of other expenses recorded for the three months ended June 30, 2022. The increase in other expenses was mainly due to higher interest expense.

Net Loss

As a result of the factors above, our net loss for the three months ended June 30, 2023 totaled approximately $4.2 million, a decrease of approximately $1.2 million, or 23%, over the approximately $5.4 million recorded for the three months ended June 30, 2022.

Consolidated Results of Operations for the Six Months Ended June 30, 2023 and 2022

The following table summarizes our consolidated results of operations for the periods indicated:

​ ​ ​ ​ Operating expenses: ​ ​ ​ ​ ​ Six Months Ended June 30, 2023 ​ ​ ​ ​ 2022 ​ ​ ​ ​ ​ ​ ​ ​ Increase (decrease) ​
Research and development expenses ​ $2,714,778 ​ $7,883,413 ​ $(5,168,635)
General and administrative expenses ​ ​ 5,529,291 ​ ​ 6,904,512 ​ ​ (1,375,221)
Total operating expenses ​ 8,244,069 ​ 14,787,925 ​ (6,543,856)
Other expenses ​ 15,816 ​ 247,059 ​ (231,243)
Net loss ​ $8,259,885 ​ $15,034,984 ​ $(6,775,099)

Research and Development Expenses

Research and development expenses include expenses primarily relating to the development of our adrulipase and niclosamide drug candidates.

Research and development expenses for the six months ended June 30, 2023 totaled approximately $2.7 million, a decrease of approximately $5.2 million, or 66%, over the approximately $7.9 million recorded for the six months ended June 30, 2022.

The decrease in research and development expenses was primarily attributable to decreases of approximately $3.7 million in clinical related expenses in connection with our Phase 2b adrulipase SPAN clinical trial during the six months ended June 30, 2023, as compared to our Phase 2 RESERVOIR COVID-19 GI clinical trial during the six months ended June 30, 2022, approximately $0.8 million in manufacturing costs related to adrulipase, as well as approximately $0.7 million in personnel related costs.

We expect research and development expenses to decrease during the remainder of this fiscal year as we work to close out the Phase 2b adrulipase SPAN clinical trial.

General and Administrative Expenses

General and administrative expenses include expenses primarily relating to our overall operations and being a public company, including personnel, legal and financial professional services, insurance, corporate communication and investor relations, listing and compliance related costs, rent, and expenses associated with obtaining and maintaining intellectual property and patents, among others.

General and administrative expenses for the six months ended June 30, 2023 totaled approximately $5.5 million, a decrease of approximately $1.4 million, or 20% over the approximately $6.9 million recorded for the six months ended June 30, 2022.

The decrease in general and administrative expenses was primarily due to decreases of approximately $0.5 million in professional fees, approximately $0.3 million in personnel related costs, approximately $0.3 million in other corporate costs, and approximately $0.2 million in public company costs, including investor relations and corporate communications.

We expect general and administrative expenses to remain stable during the remainder of this fiscal year.

Other Expenses

Other expenses for the six months ended June 30, 2023 totaled approximately $16,000, a decrease of approximately $0.2 million, or 94% over the approximately $0.2 million of other expenses recorded for the six months ended June 30, 2022. The decrease in other expenses was mainly due to the approximately $0.2 million of cash fees paid during the six months ended June 30, 2022 related to the Series B Waiver agreements.

Net Loss

As a result of the factors above, our net loss for the six months ended June 30, 2023 totaled approximately $8.2 million, a decrease of approximately $6.8 million, or 45%, over the approximately $15.0 million recorded for the six months ended June 30, 2022.

Cash Flows for the Six Months Ended June 30, 2023 and 2022

The following table summarizes our cash flows for the periods indicated:

​ ​ ​ ​ Net cash (used in) provided by: ​ ​ ​ ​ ​ Six Months Ended June 30, 2023 ​ ​ ​ ​ 2022 ​
Operating activities ​ $(5,607,262) ​ $(12,497,681)
Financing activities ​ 5,480,412 ​ 5,443,522
Net decrease in cash and cash equivalents ​ $(126,850) ​ $(7,054,159)

Operating Activities

Net cash used in operating activities during the six months ended June 30, 2023 of approximately $5.6 million was primarily attributable to our net loss of approximately $8.2 million, partially offset by non-cash expenses of approximately $0.7 million, mainly related to stock-based compensation, as well as a decrease in prepaid expenses of $0.9 million and increases in accounts payable and accrued expense of approximately $1.0 million.

Net cash used in operating activities during the six months ended June 30, 2022 of approximately $12.5 million was primarily attributable to our net loss of approximately $15.0 million, partially offset by non-cash expenses of approximately $0.8 million, mainly related to Common Stock issued to consultants of approximately $0.1 million and stock-based compensation of approximately $0.6 million, as well as increases in accounts payable and accrued expense of approximately $1.3 million and a decrease in prepaid expenses of $0.6 million.

Financing Activities

Net cash provided by financing activities of approximately $5.5 million for the six months ended June 30, 2023 was primarily due to the net proceeds of approximately $2.2 million from the exercise of warrants and $3.7 million from the March 2023 Offering, partially offset by approximately $0.4 million of cash repayments of the note payable financing for corporate insurances.

Net cash provided by financing activities of approximately $5.4 million for the six months ended June 30, 2022 was primarily due to the net proceeds of approximately $8.0 million from the March 2022 Offering of our Common Stock and warrants, partially offset by approximately $2.4 million of cash payments made related to the Merger Agreement repayments of approximately $0.5 million related to the note payable.

Critical Accounting Policies and Estimates

Our accounting policies are essential to understanding and interpreting the financial results reported on the consolidated financial statements. The significant accounting policies used in the preparation of our consolidated financial statements are summarized in Note 2 to the consolidated financial statements and notes thereto found in our Annual Report on Form 10-K for the year ended December 31, 2022. Certain of those policies are considered to be particularly important to the presentation of our financial results because they require us to make difficult, complex or subjective judgments, often as a result of matters that are inherently uncertain.

During the six months ended June 30, 2023, there were no material changes to matters discussed under the heading “Critical Accounting Policies and Significant Judgments and Estimates” in Part II, Item 7 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.

Controls and procedures

As filed, 1,462 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Disclosure Controls and Procedures

As required by Rule 13a-15(b) under the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) our Chief Executive Officer (“CEO”) and our Chief Financial Officer (“CFO”) conducted an evaluation as of the end of the period covered by this Quarterly Report on Form 10-Q, of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on that evaluation, our CEO and our CFO each concluded that our disclosure controls and procedures are effective to provide reasonable assurance that information required to be disclosed in the reports that we file or submit under the Exchange Act, (i) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and (ii) is accumulated and communicated to our management, including our CEO and our CFO, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting identified in management’s evaluation pursuant to Rules 13a-15(d) or 15d-15(d) of the Exchange Act during the period covered by this Quarterly Report on Form 10-Q that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II

OTHER INFORMATION

Risk factors

As filed, 152 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

There have been no material changes in or additions to the risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2022.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2023-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2023-04-01 to 2023-06-30$1.4mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2023-01-01 to 2023-06-30$2.7mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2023-04-01 to 2023-06-30−$4.2mus-gaap:OperatingIncomeLoss
Operating income6 months2023-01-01 to 2023-06-30−$8.2mus-gaap:OperatingIncomeLoss
Interest expense3 months2023-04-01 to 2023-06-30$5.2kus-gaap:InterestExpense
Interest expense6 months2023-01-01 to 2023-06-30$14.2kus-gaap:InterestExpense
Net income3 months2023-04-01 to 2023-06-30−$4.2mus-gaap:NetIncomeLoss
Net income6 months2023-01-01 to 2023-06-30−$8.3mus-gaap:NetIncomeLoss
Diluted EPS3 months2023-04-01 to 2023-06-30−$1.89us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2023-01-01 to 2023-06-30−$171.55us-gaap:EarningsPerShareDiluted
Basic EPS3 months2023-04-01 to 2023-06-30−$1.89us-gaap:EarningsPerShareBasic
Basic EPS6 months2023-01-01 to 2023-06-30−$3.10us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2023-04-01 to 2023-06-302,270,922 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2023-01-01 to 2023-06-302,725,755 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2023-01-01 to 2023-06-30−$5.6mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2023-06-30$1.2mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2023-06-30$2.4mus-gaap:AssetsCurrent
Total assetsAt period end2023-06-30$4.3mus-gaap:Assets
Current liabilitiesAt period end2023-06-30$3.3mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2023-06-30$3.4mus-gaap:Liabilities
Shareholders' equityAt period end2023-06-30$882.0kus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001410578-23-001882. Last ingested by Listed: Oct 30, 2026, 17:12 ET. Listed shows no prices and gives no investment advice.